A Case of Immune-Related Adverse Events, Including Myasthenia Gravis, Myositis, and Myocarditis, during Avelumab and Axitinib Combination Therapy
Myasthenia gravis, myositis, and myocarditis can occur during avelumab and axitinib combination therapy for RCC. Prompt diagnosis, treatment, and collaboration with other departments are extremely important for managing irAEs.
Authors
- Jun-ichi Teranishi
- Daiji Takamoto (ORCID: https://orcid.org/0009-0007-5173-6228)
- Kimito Osaka (ORCID: https://orcid.org/0000-0003-4110-7130)
- Yohei Hanajima (ORCID: https://orcid.org/0000-0003-4214-2886)
- Jurii Karibe
- Ryo Horiguchi (ORCID: https://orcid.org/0009-0008-4842-9128)
- Naohisa Ueda (ORCID: https://orcid.org/0000-0001-6610-058X)
- Hiroji Uemura (ORCID: https://orcid.org/0000-0001-7943-1564)
- Akihito Hashizume (ORCID: https://orcid.org/0009-0008-1054-0779)
- Takashi Kawahara (ORCID: https://orcid.org/0000-0001-6494-819X)
Institutions
- Yokohama City University Medical Center (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1159/000545733
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09